Drug-induced Lupus Erythematosus
GPTKB entity
Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
autoimmune disease
lupus erythematosus |
| gptkbp:antibodyTarget |
anti-histone antibody
|
| gptkbp:associatedWith |
gptkb:isoniazid
gptkb:minocycline quinidine procainamide hydralazine |
| gptkbp:causedBy |
certain medications
|
| gptkbp:commonIn |
gptkb:African-American
gptkb:women older adults |
| gptkbp:diagnosedBy |
antinuclear antibody test
anti-histone antibody test |
| gptkbp:differentialDiagnosis |
gptkb:systemic_lupus_erythematosus
|
| gptkbp:firstDescribed |
1945
|
| https://www.w3.org/2000/01/rdf-schema#label |
Drug-induced Lupus Erythematosus
|
| gptkbp:prevalence |
rare
|
| gptkbp:prognosis |
usually resolves after stopping drug
|
| gptkbp:symptom |
fever
fatigue rash arthralgia myalgia serositis |
| gptkbp:treatment |
gptkb:NSAIDs
corticosteroids discontinuation of causative drug |
| gptkbp:bfsParent |
gptkb:Lupus_Erythematosus
|
| gptkbp:bfsLayer |
7
|